Clinical Trial Update: Nituzumab (Taixinsheng ®） A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study on the Efficacy and Safety of Combined Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinomatreatment of Locally Advanced Nasopharyngeal Carcinoma [Phase 2]

View source ↗

Summary

This Clinical Trial Update describes a Phase II randomized, double-blind, placebo-controlled multicenter study evaluating Nituzumab (Taixinsheng) in combination…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Taixinsheng (Nituzumab)

Snippet

Sponsor: Sichuan Cancer Hospital and Research Institute | Conditions: Nasopharyngeal Carcinoma | Phase 2 | Status: RECRUITING